



Disclaimer

This presentation (the "Presentation") was made by Intelicanna. This Presentation is provided on a strictly private and confidential basis for information purposes only. By attending or reading this Presentation, you will be deemed to have agreed to the obligations and restrictions set out below. Without the express prior written consent of the Intelicanna's directors, the Presentation and any information contained within it may not be (i) reproduced (in whole or in part), (ii) copied at any time, (iii) used for any purpose other than your evaluation of Intelicanna, or (iv) provided to any other person, except your employees and advisors with a need to know who are advised of the confidentiality of the information. This Presentation does not constitute or form part of, and should not be construed as, an offer, invitation or inducement to purchase or subscribe for securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This Presentation does not constitute either advice or a recommendation regarding any securities. The communication of this Presentation is restricted by law; it is not intended for distribution to, or use by, any person in any jurisdiction where such distribution or use would be contrary to local laws or regulations. This Presentation may contain forecasts and forward looking information. Such forecasts, projections and information are not a guarantee of future performance, and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ materially from those expressed or implied. Intelicanna has not audited or investigated the accuracy or completeness of the information, statements and opinions contained in this Presentation. Accordingly, to the maximum extent permitted by applicable laws, Intelicanna makes no representations and can give no assurances, guarantees or warranties, expressed or implied, as to, and takes no responsibility and assumes no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statements or opinions in this Presentation. You should not act or refrain from acting in reliance on this Presentation material. This overview of Intelicanna does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of Intelicanna's prospects. You should conduct your own investigation and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions in this Presentation before making any investment decision.



OUR TEAM



Ori Weiss CEO

CEO and Director at Intelicanna.

Ori is an entrepreneur and businessman in the fields of real estate, capital markets and agriculture. Ori was previously a partner in the "Israeli Construction Center Group" and a Director of "the Israeli Housing Center". Ori's real estate ventures include residential and commercial projects throughout Israel.



Doron Birger
Chairman and
Consultant

Doron is a technology consultant that formerly served as CEO of Elron as well as chairman of Given Imaging, a company that later sold for approximately one billion dollars. Both companies dual traded on the TASE and NASDAQ. Doron serves as chairman, director and consultant to a number of non-profits and technology companies, with a focus on the field of medical devices



Nachshol Cohen CTO

Nachshol has over 10 years' experience in industrial scale cultivation of cannabis, and is considered an Israeli pioneer in the field. Mr. Cohen also founded Integral-Hydroponics and Mycolivia and was the breeder and grower of IMC (Israel Medicinal Cannabis).



Ilanit Halperin CFO

Mrs. Halperin has over 20 Years' experience in accounting, including 11 as a partner at one of the largest firms in Israel. She has extensive experience with public companies in Israel and abroad. Ilanit is familiar with international accounting standards (IFRS), U.S. accounting standards (US GAAP) and Israel accounting standards (ISRAEL GAAP).



Dr. Dov TamarkinDirector and Consultant

Dr. Tamarkin is a former founder and CEO of Foamix, a developer and marketer of innovative dermatology drugs. In 2014, the company listed on the NASDAQ and raised \$160 million. At Intelicanna, Dr. Tamarkin serves as a Director, with responsibility for leading projects in the area of medical treatment development based on cannabis and its derivatives.



COMPANY ASSETS

Full Ownership of a 5,500sqm (With an enlargemet option for about 3sqm hybrid GMP grade, cultivation facility in HaSharon) that is considered one of the leading facilities in Israel With a production capacity between 5-10 tons a year, and its own genetics tactility.



Logistics & Distribution – Intelicanna has 37% of a partnership with Neopharm Group to establish a dispensary, logistics and distribution center to distribute cannabis products to Pharmacies. We expect it to be the strongest and most extensive cannabis marketing force in Israel.

Collaboration with Moraz Medical Herbs. Intelicanna has 49% of this collaboration to create and distribute a line of products that combine Intelicanna's CBD with Moraz's existing paramedical cosmetic formulas. Sales are projected to begin - Q2 2021.

Pet Food Collaboration – Intelicanna has 50% of a collaboration with Bar Magen and Vet Magen to create a line of products that combine Intelicanna's CBD with their existing pet and farm animal food and supplement formulations.





ISRAELI CULTIVATION FACILITY



Size

5,500 sqm GMP farm in a 22,000 sqm Plot.

Location

HaSharon District

Continuous Cultivation 365 Growing Days

Production Capacity4 Tons Annually

Cultivation EnvironmentHybrid Greenhouse

Future FarmingFully Automated



OUR FLOWERS

Our medical cannabis inflorescences are grown under optimal and consistent conditions; and then transferred to our EU-GMP Post-Harvest clean rooms unit.

Our first 3 strains are already available in 150 pharmacies.





OUR PARTNERS





JV with Neopharm Group to Sell and Distribute Cannabis Products.

The Neopharm JV will allow Intelicanna to profit on the distribution of competitor brands that are distributed directly to consumers via the joint venture, creating an additional profit center for the company.

Neopharm is one of the largest pharmaceutical distributors in Israel and has a well-established distribution chain in place.

The JV will sell and distribute cannabis products from the top companies in the industry directly to patients. The distribution will be via a dispensary center, a pharmacy, and an online app.

An estimated 20% of cannabis consumers currently take advantage of home delivery, and this market is projected to more than double to 50% next year.





COLLABORATIONS

Collaboration with Moraz Herbs

The collaboration will engage in the development, import, export and manufacture of cosmetics and skin care, based on herbal extracts.

For the purpose of joint venture, Moraz and Intelicanna will produce, distribute and sale Cannabis-based medical products in the field of skin care.

The cannabis will be integrated as an additional ingredient in the existing formula of the products, as well as new products to be developed. This cooperation will enable marketing of first products during 2021. Moraz currently operates in over 19 countries (including Israel) and has tens of millions in sales cycles.

Regulators are currently working to approve the opening of the CBD market in Israel.












VENTURES

INTELICANNAS' GREENCUBATOR

Promoting along our medical inflorescence; companies who strive to better the medical cannabis filed in


- Agriculture
- Technology
- Medicine

First Rights - Intelicanna will receive the developed products for its own use as a beta site of the venture and Incubator investors will have the right to invest directly in each venture.





ISRAELI MARKET



Market Growth



Since the 2019 reform law, the cannabis market has grown by 112% to 76,772 patients.

Average Consumption



The average monthly cannabis consumption per patient is 35 grams

Price Per Gram



The average price for patients per gram is 25 –30 ILS

Pharmacies Profit Data

About 30% gross profit

Manufacturer Sales Data

Average price of a manufacturer is about 17 NIS per gram

Consumer Data

Average consumption of 35 grams per month



CONCLUSION & FUTURE GROWTH

Uniqueness

With one of the leading cultivation facilities in Israel and its own unique starins, Intelicanna will continue to invest in innovations to make the company a technology hub within the industry.

Global Expansion

Apart from growing in Israel; Intelicanna will continue to diversify its business and revenue by developing additional CBD products to market in Israel and the EU, and will continue its search for interesting ventures in the field.

Diversity

Intelicanna has entered into partnerships and collaborations with various industry leaders in a variety of fields to expand its portfolio and diversify its revenue streams.

The Right Team

Intelicanna's management team has experience, knowledge and significant international business connections in the field of cannabis.





liron@intelicann.com | +972-526-938998